参麦注射液联合沙库巴曲缬沙坦治疗慢性心力衰竭临床研究  

Clinical Study on Shenmai Injection Combined with Sacubitril Valsartan for Chronic Heart Failure

作　　者：王晓琼 王耀辉[1] 段新杰[1] 潘金生[1] 李英[1] 张静[1] WANG Xiaoqiong;WANG Yaohui;DUAN Xinjie;PAN Jinsheng;LI Ying;ZHANG Jing

机构地区：[1]平顶山市第一人民医院,河南平顶山467000

出　　处：《新中医》2022年第4期47-50,共4页New Chinese Medicine

基　　金：国家自然科学基金项目(81970259)。

摘　　要：目的:观察参麦注射液联合沙库巴曲缬沙坦治疗慢性心力衰竭(CHF)的临床疗效。方法:选取118例CHF患者,根据随机数字表法分为观察组和对照组各59例。对照组给予沙库巴曲缬沙坦钠片治疗,观察组在对照组基础上给予参麦注射液治疗。比较2组治疗前后心功能分级、左室射血分数(LVEF)、左室舒张末期内径(LVDD),以及氨基末端脑钠肽前体(NT-proBNP)、可溶性CD40配体(sCD40L)、妊娠相关血浆蛋白(PAPP-A)水平。结果:治疗后,2组心功能分级均较治疗前降低(P<0.05),观察组心功能分级低于对照组(P<0.05)。治疗后,2组LVEF均较治疗前升高(P<0.05),NT-proBNP、sCD40L及PAPP-A水平均较治疗前降低(P<0.05),LVDD均较治疗前减小(P<0.05);观察组LVEF高于对照组(P<0.05),NT-proBNP、sCD40L及PAPP-A水平均低于对照组(P<0.05),LVDD小于对照组(P<0.05)。结论:参麦注射液联合沙库巴曲缬沙坦治疗CHF疗效较好,可改善患者的心功能,降低NT-proBNP、sCD40L、PAPP-A水平。Objective:To observe the clinical effect of Shenmai injection combined with sacubitril valsartan for chronic heart failure(CHF).Methods:A total of 118 cases of CHF patients were selected and divided into the observation group and the control group according to the random number table method,with 59 cases in each group.The control group was treated with sacubitril valsartan sodium tablets,and the observation group was additionally treated with Shenmai injection based on the treatment of the control group.Before and after treatment,heart function grading,left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVDD) and the levels of N-terminal pro-brain natriuretic peptide(NT-proBNP),soluble CD40 ligand(sCD40 L) and pregnancy-associated plasma proteins(PAPP-A) in the two groups were compared.Results:After treatment,the heart function grading in the two groups was decreased when compared with that before treatment(P<0.05),and the heart function grading in the observation group was lower than that in the control group(P<0.05).After treatment,the levels of LVEF in both group were increased when compared with those before treatment(P<0.05),the levels of NT-proBNP,sCD40 L and PAPP-A were decreased(P<0.05),and LVDD were smaller(P<0.05).The levels of LVEF in the observation group was higher than that in the control group(P<0.05),the levels of NT-proBNP,sCD40 L and PAPP-A were lower(P<0.05),and LVDD was smaller(P<0.05).Conclusion:The therapy of Shenmai injection combined with sacubitril valsartan for CHF has a good curative effect,and can improve the heart function of patients and reduce the levels of NT-proBNP,sCD40 L and PAPP-A.

关 键 词：慢性心力衰竭 参麦注射液 沙库巴曲缬沙坦 心功能 氨基末端脑钠肽前体 可溶性CD40配体 妊娠相关血浆蛋白 

分 类 号：R541[医药卫生—心血管疾病]